Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
  • A61K36/062—Ascomycota
  • A61K36/064—Saccharomycetales, e.g. baker's yeast
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K10/00—Animal feeding-stuffs
  • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
  • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/163—Sugars; Polysaccharides
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K50/00—Feeding-stuffs specially adapted for particular animals
  • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K10/00—Animal feeding-stuffs
  • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
  • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
  • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/174—Vitamins
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/195—Antibiotics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/20—Inorganic substances, e.g. oligoelements
  • A23K20/30—Oligoelements

Definitions

• the present invention relates to the field of health, in particular animal health.
• the invention relates more particularly to cell wall extracts of Saccharomyces cerevisiae yeast rich in O-glucans, and their use in the prevention or treatment of a disease associated with or caused by an infection with Lawsonia intracellularis in pigs.
• Lawsonia intracellularis an obligate intracellular gram-negative bacterium, is the etiological agent of porcine ileitis. Ileitis, also called proliferative enteropathy, is one of the most common digestive diseases affecting growing pigs worldwide.
• the characteristic pathological feature of the disease is the proliferation of immature epithelial cells in the crypts of the ileum (terminal part of the small intestine), the large intestine, or both. Sections of infected tissue are characterized by a reddish thickening of the mucosa, resembling a "garden hose", and enteric lesions. Thickening of the intestine eventually prevents normal intestinal function, absorption capabilities, and nutrient transfer. The clinical effects of the disease are chronic weight loss, poor appetite, diarrhea and death.
• the disease can be expressed in acute or chronic form.
• chronic form mainly affecting pigs aged 6 to 20 weeks, the clinical signs are crude: reduction in growth performance associated or not with diarrhea. As a result, the disease can often go unnoticed.
• the acute form characterized by bloody diarrhea and sudden mortality affects pigs aged 4 to 12 months. In contaminated herds, the disease is responsible for significant economic losses for the breeder due to the reduction in technical performance, the increase in the cost of medication and the resulting mortality.
• extracts of Saccharomyces cerevisiae yeast walls rich in 0-glucans significantly improve the immunity of pigs exposed to Lawsonia intracellularis, and therefore make it possible to prevent and/or treat infections. by this bacteria, and/or diseases associated with or caused by this bacteria, in particular ileitis.
• the Inventors were able to demonstrate that the treatment with extracts of Saccharomyces cerevisiae yeast walls rich in 0-glucans according to the invention of pigs exposed to Lawsonia intracellularis, made it possible to promote the weight gain of the pigs. and reduce the incidence of infection within the herd.
• Saccharomyces cerevisiae yeast wall extracts rich in p-glucans can advantageously be administered orally, in particular via food, and can therefore act more directly in the intestine. , where the pathogen is mainly present.
• the subject of the present invention is an extract of cell walls of Saccharomyces cerevisiae yeast rich in O-glucans for use in the prevention or treatment of a disease associated with or caused by Lawsonia intracellularis infection in pigs, characterized in that the extract comprises O-glucans and mannans, where the p -glucans are present in the form of a mixture of P -1,3-glucans and £ -1,6-glucans in a total quantity greater than or equal to 50% by weight, in particular between 50% and 99% by weight, and where the mannans are present in a total quantity of less than 5% by weight, in particular between 1% and 5% by weight.
• the disease is an inflammatory bowel disease, particularly ileitis.
• the total quantity of [3 -glucans present in an extract of cell walls of Saccharomyces cerevisiae yeast rich in [3 -glucans is between 50% and 90% of the weight of the extract, for example between 50 % and 80%, or between 50% and 70%, or between 50 and 60%, of the weight of the extract.
• the total quantity of mannans present in an extract of cell walls of Saccharomyces cerevisiae yeast rich in [3-glucans is between 2% and 4% of the weight of the extract.
• the quantity of mannans in the cell wall extract of Saccharomyces cerevisiae yeast rich in [3-glucans is such that the ratio [3-glucans/mannans is between 12 and 40 (weight/weight).
• the quantity of mannans in the cell wall extract of Saccharomyces cerevisiae yeast rich in [3-glucans is such that the ratio [3-glucans/mannans is between 15 and 30 (weight/weight), especially between 18 and 22 (weight/weight).
• the cell wall extract of Saccharomyces cerevisiae yeast rich in [3-glucans is characterized in that it has a dry matter content greater than or equal to 94% by weight, in particular greater than or equal to 96% by weight.
• the cell wall extract of Saccharomyces cerevisiae yeast rich in [3-glucans is characterized in that it further comprises a protein content less than or equal to 10% by weight, and a glycogen content less than or equal to 10% by weight.
• the Saccharomyces cerevisiae yeast cell wall extract rich in [3-glucans is characterized in that the [3-glucans and mannans are the only active ingredients of the Saccharomyces yeast cell wall extract cerevisiae rich in [3-glucans.
• the cell wall extract of Saccharomyces cerevisiae yeast rich in [3-glucans is characterized in that it is Safglucan® which comprises [3-glucans and mannans, where the [3 -glucans are present in the form of a mixture of [3-1, 3-glucans and (3-1, 6-glucans in a total quantity of between 52 and 60% by weight; and the mannans are present in a total amount of between 1 and 5% by weight, and where the Safglucan® further comprises a protein content less than or equal to 10% by weight, and a glycogen content less than or equal to 10% by weight. weight.
• the invention relates to a composition
• a composition comprising an extract of cell walls of Saccharomyces cerevisiae yeast rich in p -glucans and at least one bioactive agent for use in the prevention of an infection associated with the bacteria Lawsonia intracellularis in the pig, characterized in that the extract is as defined in the present description.
• the bioactive agent is selected from the group consisting of antibiotics, vaccines, probiotics, prebiotics, vitamins, minerals, trace elements, and mixtures thereof.
• the subject of the invention is a pharmaceutical composition
• a pharmaceutical composition comprising an extract of cell walls of Saccharomyces cerevisiae yeast rich in O-glucans and at least one physiologically acceptable excipient for use in the prevention or treatment of an associated infection to the Lawsonia intracellularis bacteria in pigs, characterized in that the extract is as defined in the present description.
• the invention relates to a feed for pigs comprising an extract of cell walls of Saccharomyces cerevisiae yeast rich in O-glucans for use in the prevention of a disease associated with or caused by Lawsonia intracellularis infection in pigs. , characterized in that the extract is as defined in the present description or is part of a composition as defined in the present description.
• Figure 1 shows the weight of the animals during the test period.
• the present invention relates to cell wall extracts of Saccharomyces cerevisiae yeast rich in O-glucans for use in the prevention or treatment of a disease associated with or caused by an infection with Lawsonia intracellularis in animals, in particular pig, characterized in that said extracts comprise P-glucans and mannans, where the p-glucans are present in the form of a mixture of P -1,3-glucans and p -1,6-glucans in an amount total greater than or equal to 50% by weight, in particular between 50% and 99% by weight, and where the mannans are present in a total quantity less than 5% by weight, in particular between 1% and 5% by weight.
• the animal to which the invention applies is an animal chosen from farm animals and pets, in particular the pig, or the horse.
• pig refers to the porcine animal species in general.
• the p-glucans of an extract according to the invention are obtained from a Saccharomyces cerevisiae yeast, and more particularly from a Saccharomyces cerevisiae yeast strain.
• Saccharomyces cerevisiae yeast strain Numerous strains of Saccharomyces cerevisiae are known in the art. They are largely used in the food industry for their role in the manufacture of several foods, notably breads and fermented drinks.
• yeast strain designates a relatively homogeneous population of yeast cells obtained by cultivation (or multiplication) of the starting strain.
• a yeast strain is obtained from a clone, a clone being a population of yeast cells obtained from a single yeast cell.
• the cultivation of a Saccharomyces cerevisiae yeast strain can be carried out by any suitable method. Yeast cultivation processes are known in the prior art, and those skilled in the art know how to optimize the cultivation conditions for each strain according to its nature.
• a Saccharomyces cerevisiae yeast can be obtained by multiplication of a strain in an appropriate culture medium, for example, as described in the reference book “Yeast Technology”, 2nd edition, 1991, G. Reed and T.W. Nagodawithana, published by Van Nostrand Reinhold, ISBN 0-442-31892-8.
• yeast cell walls and “yeast hulls” are used interchangeably here and refer to the insoluble fraction of yeast cells, i.e. the yeast cell wall and plasma membrane.
• the yeast cell walls are obtained by a process comprising an enzymatic autolysis or hydrolysis step, essentially by proteases, followed by a step of separation of the soluble fraction and the insoluble fraction, the fraction isolated insoluble corresponding to yeast cell walls. The insoluble fraction can then be dried.
• the process for obtaining yeast cell walls is such that it preserves the structural polysaccharides of the cell wall, that is to say p-glucans and mannans, these mannans being in the form of mannoproteins.
• yeast cell walls are known in the art (see for example the reference work “Yeast Technology”, 2nd edition, 1991, G. Reed and T.W. Nogodawithana, published by Van Nostrand Reinhold, New York , ISBN 0-442-31892-8).
• An extract of Saccharomyces cerevisiae yeast cell walls rich in p-glucans refers to a fraction which has been extracted (or isolated) from the cell walls and which mainly contains P-glucans.
• p-glucans from the yeast cell wall are called “wall 0-glucans”. They are essentially glucose polymers whose glucose units in the main chain are linked by 3-1,3 bonds and whose branches are linked by 0-1,6 bonds.
• Yeast P-glucans are insoluble and have low viscosity. Those skilled in the art know how to extract O-glucans from the yeast cell wall.
• a common method includes successive hot extractions with a base and with an acid (such as acetic acid), followed by aqueous washes to remove any soluble compounds from the cell walls, and recovery of the insoluble material consisting of cell wall 0-glucans. .
• an acid such as acetic acid
• a Saccharomyces cerevisiae yeast cell wall extract rich in 0-glucans according to the present invention comprises a total quantity greater than or equal to 50% by weight of 0-glucans in the form of a mixture of p-1,3-glucans and 0 -1,6-glucans.
• total quantity greater than or equal to 50% by weight of 0-glucans means that the 0-glucans represent at least half of the weight of the extract according to the invention.
• the total quantity of O-glucans present in an extract according to the invention can represent between 50% and 90% of the weight of the extract, for example between 50% and 80%, or between 50% and 70%, or still between 50 and 60% of the weight of the extract.
• the total quantity of O-glucans present in an extract according to the invention represents between 50% and 65%, for example, approximately 51%, approximately 52%, approximately 53%, approximately 54%, approximately 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, or about 65% of the weight of the extract.
• a Saccharomyces cerevisiae yeast cell wall extract rich in O-glucans according to the present invention also contains mannans in a total quantity of less than 5% by weight. Mannans from the yeast cell wall are called “wall mannans”. These are yeast polysaccharides consisting mainly of mannose and more precisely copolymers of neutral or acidic oses (with 5 or 6 carbon atoms), linked together by glycosidic bonds and linked to proteins.
• mannose is present in the form of a skeleton of mannose residues (50 or more) linked in a-(1,6), branched by short chains of mannose linked in a- (1,2) and in a-(1,3).
• total quantity less than 5% by weight of mannans means that the mannans represent at most 5% of the weight of the extract according to the invention.
• the total quantity of mannans present in an extract according to the invention can represent between 0.5% and 5% of the weight of the extract, in particular between 0.5% and 1.5% of the weight of the extract. .
• an extract of Saccharomyces cerevisiae yeast cell walls rich in 0-glucans comprises 0-glucans and mannans, where the 0-glucans are present in the form of a mixture of 0-1,3-glucans and 0-1,6-glucans in a total amount greater than or equal to 50% by weight; and the mannans are present in a total quantity such that the p-glucan/mannan ratio is between 12 and 40 (w/w).
• the O-glucan/mannan ratio in an extract according to the invention can be between 15 and 30 (weight/weight), and more particularly between 18 and 22 (weight/weight).
• a Saccharomyces cerevisiae yeast cell wall extract rich in O-glucans according to the present invention further comprises a protein content of less than or equal to 10% by weight, and a glycogen content of less than or equal to 10 % in weight.
• an 0-glucan-rich Saccharomyces cerevisiae yeast cell wall extract according to the present invention comprises, as the only active ingredients, 0-glucans and mannans, where the 0-glucans are present in the form of a mixture of 0-1,3-glucans and 0-1,6-glucans in a total amount greater than or equal to 50% by weight; and the mannans are present in a total quantity of less than 5% by weight such that the p-glucan/mannan ratio is between 12 and 40 (weight/weight), in particular between 15 and 30 (weight/weight), and more especially between 18 and 22 (weight/weight).
• an extract of Saccharomyces cerevisiae yeast cell walls according to the invention has a dry matter content greater than or equal to 94% by weight, preferably greater than or equal to 96% by weight.
• a dry matter content greater than or equal to 94%, preferably 96% by weight allows better conservation of yeast hulls, in particular better bacteriological stability and better stability with respect to undesirable reactions of enzymatic origin or not.
• an extract of cell walls of Saccharomyces cerevisiae yeast according to the invention is in powder form.
• the cell wall extract of Saccharomyces cerevisiae yeast rich in 0-glucans according to the invention is Safglucan® which is produced by the Applicant, Lesaffre.
• Safglucan® includes 0-glucans and mannans, as the only active ingredients, where the 0-glucans are present as a mixture of 0-1,3-glucans and 0-1,6-glucans in one total quantity between 52 and 60% by weight; and the mannans are present in a total amount of between 1 and 5% by weight.
• Safglucan® also includes a protein content of less than or equal to 10% by weight, and a glycogen content of less than or equal to 10% by weight.
• an extract of Saccharomyces cerevisiae yeast cell walls according to the invention can be packaged and/or stored in suitable conditions, generally a dry and cool place, before use.
• suitable conditions generally a dry and cool place, before use.
• the shelf life of a cell wall extract according to the invention, in suitable packaging, is 2 years from the date of production.
• compositions Comprising an Extract of Cell Walls of Saccharomyces cerevisiae Yeast Rich in p-Glucans
• the cell wall extracts of Saccharomyces cerevisiae yeast rich in 0-glucans described here are used as such, in particular in the absence of any other active substance.
• the O-glucan-rich Saccharomyces cerevisiae yeast cell wall extracts described herein are used in combination with at least one other bioactive agent. Consequently, the present invention relates to a composition comprising an extract of cell walls of Saccharomyces cerevisiae yeast rich in O-glucans, as described here, combined with at least one bioactive agent.
• bioactive agent means an agent beneficial to animal health. It may be a veterinary active substance, having a therapeutic or preventive effect.
• the bioactive agent can, for example, be chosen from antibiotics, vaccines, probiotics or prebiotics, or mixtures thereof.
• the bioactive agent is chosen from antibiotics, vaccines or prebiotics.
• bioactive agent also designates substances having a beneficial effect on the nutritional level, in particular nutrients, such as for example vitamins, minerals, or trace elements, in particular those which are generally found in animal food supplements, supplements or additives.
• compositions according to the invention can be found in any form, for example in the form of powder, granules, a gel or a liquid.
• the compositions according to the invention are in solid form, preferably in powder form.
• the invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising an extract of cell walls of Saccharomyces cerevisiae yeast rich in O-glucans, as described here, and at least one physiologically acceptable excipient in veterinary medicine.
• the extract may be present as the only active ingredient.
• the pharmaceutical composition may also comprise at least one other bioactive agent, such as those listed above.
• a pharmaceutical composition according to the invention can be classified as a veterinary pharmaceutical preparation available by prescription or over the counter.
• physiologically acceptable excipient in veterinary medicine means any medium or additive which does not interfere with the effectiveness of the biological activity of the active principle (here the extract of cell walls rich in 0-glucans), and which is not excessively toxic to the animal, at the concentrations at which it is administered.
• the veterinary pharmaceutical compositions according to the present invention can be administered using any combination of dosage and route of administration effective to achieve the desired prophylactic effect.
• the pharmaceutical compositions are administered orally.
• the exact quantity to be administered to pigs may vary depending on the weight of the animal, and the effects of Lawsonia intracellularis on the animal to be treated.
• Lawsonia intracellularis infections cause inflammation of the intestine in pigs, particularly ileitis, which causes diarrhea and even cases of sudden death. They therefore result in a reduction in feed efficiency and weight gain of the animal.
• the O-glucan-rich Saccharomyces cerevisiae yeast cell wall extracts described herein have been shown to significantly reduce symptoms associated with Lawsonia intracellularis infection.
• the invention therefore also relates to an extract of cell walls of Saccharomyces cerevisiae yeast rich in 0-glucans, as described here, alone or combined with at least one bioactive agent, for use in the prevention or treatment of a Lawsonia infection. intracellularis in pigs.
• the invention therefore also relates to an extract of cell walls of Saccharomyces cerevisiae yeast rich in 0-glucans, as described here, alone or combined with at least one bioactive agent, for use in the prevention or treatment of an associated disease or caused by Lawsonia intracellularis infection in pigs.
• the disease associated with or caused by Lawsonia intracellularis may be intestinal inflammation, particularly selected from the group consisting of enteritis, or ileitis.
• the invention also provides an extract of cell walls of Saccharomyces cerevisiae yeast rich in 0-glucans, as described here, alone or combined with at least one bioactive agent, for use in the prevention or treatment of inflammatory intestinal diseases in pigs. , especially associated with or caused by Lawsonia intracellularis infection, such as ileitis.
• prevention refers to any act aimed at preventing or delaying the onset of a disease, in particular reducing or inhibiting, partially or totally, the probability that a subject develops one or more symptoms linked to a disease associated with or caused by Lawsonia intracellularis infection (diarrhea, reduction in body weight, thickening of the intestinal wall, etc.).
• Lawsonia intracellularis infection diarrhea, reduction in body weight, thickening of the intestinal wall, etc.
• prevention and “prophylactic treatment” are equivalent and can be used interchangeably in the context of the present invention. Prevention can aim both subjects with a predisposition to infections, preferably intestinal infections, and non-predisposed subjects.
• treatment refers to any act aimed at improving the medical status of a subject suffering from a disease.
• the treatment can aim both at an improvement in the patient's condition, that is to say at a regression of the disease or certain of its symptoms, and at an eradication of the disease or certain of its symptoms. .
• Treatment may also have the effect of preventing or slowing the progression of a disease.
• the extracts or compositions are intended for the prevention of disease associated with or caused by Lawsonia intracellularis in pigs.
• the use of a cell wall extract of Saccharomyces cerevisiae yeast rich in P-glucans, alone or combined with at least one bioactive agent, in the prevention of a disease associated or caused by the bacteria Lawsonia intracellularis comprises the mixture of an extract of cell walls of yeast Saccharomyces cerevisiae rich in 0-glucans with an animal feed. Mixing can be done by any suitable method known in the art.
• animal food means any natural or processed organic material that is susceptible to biodegradation and that can be consumed by an animal.
• organic materials range from freshly harvested grains to pelleted feeds, and include for example any compound, grain, nut, forage, silage, preparation, composition or mixture suitable for or intended to be ingested by an animal.
• the animal food may in particular be in the form of granules, liquid, porridge or mixture of flours (“mash feed” in English).
• the term “fodder” refers to plant material (mainly leaves and stems of plants) consumed by grazing animals.
• the term “silage” refers to a fermented forage with a high moisture content that can be used as feed for ruminants.
• the preparations, compositions and mixtures e.g. commercial preparations, compositions and mixtures, may be in any suitable form, e.g. in the form of concentrates, premixes, supplements, total mixed ration (TMR), etc. .
• the animal food may contain cereals (e.g. corn, wheat, barley, rye, rice, sorghum, millet or any combination thereof), fodder, silage, legumes (e.g. soya), spent grains, animal products, etc.
• Spent grains mainly come from industrial processes such as brewing and distilleries, intended for the production of drinking alcohol (whiskey, vodka or gin) or biofuels. Brewers grains are produced from malt, itself derived from barley. Cereals other than barley can occasionally be used in brewing, such as sorghum, particularly in Africa. The spent grains from the manufacture of bioethanol are made from corn or wheat. Wet grains are dried to produce dry grains, which are mainly used as animal feed.
• a Saccharomyces cerevisiae yeast cell wall extract rich in [3-glucans, as described herein, alone or in combination with at least one bioactive agent, can be added to an animal feed in quantities of approximately 0.02% at approximately 0.05% by total weight of food (which corresponds to quantities of approximately 200 g to approximately 500 g per tonne of food) subject to compliance with current legislation.
• a Saccharomyces cerevisiae yeast cell wall extract rich in [3-glucans, as described herein, alone or in combination with at least one bioactive agent is added to an animal feed in a quantity of approximately 0.02% to approximately 0.05% by total weight of the food (which corresponds to a quantity of approximately 200 to approximately 500 g per ton of food), for example in a quantity of approximately 0.02% to approximately 0.05% by weight of food (which corresponds to approximately 200 to approximately 500 g per ton of food).
• the extract or the compositions according to the invention can be administered for the entire duration of the infection or the entire duration of the risk of infection. It can in particular be administered continuously, with food, to prevent diseases associated with or caused by the Lawsonia intracellularis bacteria and/or Lawsonia intracellularis infections.
• 160 piglets (Danbred x Duroc) are obtained from a commercial farm and are placed in a fattening unit in which the bacteria Lawsonia intracellularis is present. On arrival at the farm, they are individually weighed and ear-marked. The animals are then divided into two groups (1 control group and 1 treated group) of 80 pigs each. The animals are separated into subgroups of 10 animals. The control receives conventional power. The treated group receives normal food in which beta glucan product (250ppm) has been included for the entire duration of the trial. The animals from the 2 groups were weighed on days 63, 81 and 97 and their feces were collected at the same time to detect, by quantitative qPCR, the presence of the Lawsonia intracellularis bacteria.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Microbiology (AREA)
• Animal Husbandry (AREA)
• Zoology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Communicable Diseases (AREA)
• Physiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Birds (AREA)
• Oncology (AREA)
• Biochemistry (AREA)
• Alternative & Traditional Medicine (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Fodder In General (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Feed For Specific Animals (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85037151

Family Applications (1)

Country Status (10)

Family Cites Families (1)

• 2022
  • 2022-07-20 FR FR2207447A patent/FR3138028A1/fr active Pending
• 2023
  • 2023-01-13 US US18/996,253 patent/US20260027170A1/en active Pending
  • 2023-07-13 JP JP2025502585A patent/JP2025523169A/ja active Pending
  • 2023-07-13 EP EP23764357.2A patent/EP4558155A1/de active Pending
  • 2023-07-13 CN CN202380054633.8A patent/CN119497623A/zh active Pending
  • 2023-07-13 WO PCT/FR2023/051091 patent/WO2024018140A1/fr not_active Ceased
  • 2023-07-13 AU AU2023310952A patent/AU2023310952A1/en active Pending
  • 2023-07-20 AR ARP230101898A patent/AR129969A1/es unknown
• 2025
  • 2025-01-15 ZA ZA2025/00506A patent/ZA202500506B/en unknown
  • 2025-01-17 MX MX2025000739A patent/MX2025000739A/es unknown

Also Published As

Similar Documents

Legal Events